{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:47:54Z","timestamp":1767703674555,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.msard.2016.06.012","type":"journal-article","created":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T14:02:42Z","timestamp":1467036162000},"page":"50-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Interferon \u03b2 associated nephropathy in a Multiple Sclerosis patient: A case and review"],"prefix":"10.1016","volume":"9","author":[{"given":"Musa","family":"Ozturk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulya","family":"Basoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murvet","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayse Aysim","family":"Ozagari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevim","family":"Baybas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.msard.2016.06.012_bib1","first-page":"425","article-title":"Beta interferon induced nephritic syndrome in patients with multiple sclerosis","volume":"54","author":"Gotsman","year":"2000","journal-title":"Clin. Nephrol."},{"issue":"3","key":"10.1016\/j.msard.2016.06.012_bib2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1017\/S0317167100004303","article-title":"Nephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a","volume":"25","author":"Auty","year":"2005","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.msard.2016.06.012_bib3","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s00415-003-1090-4","article-title":"Recurrent nephrotic syndrome in patient with multiple sclerosis treated with interferon beta-1a","volume":"250","author":"Tola","year":"2003","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2016.06.012_bib4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s10157-006-0424-9","article-title":"Nephrotic syndrome associated with interferon beta-1b therapy for multiple sclerosis","volume":"10","author":"Kumasaka","year":"2006","journal-title":"Clin. Exp. Nephrol."},{"issue":"1","key":"10.1016\/j.msard.2016.06.012_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5692\/clinicalneurol.53.19","article-title":"Nephrotic syndrome in multiple sclerosis patients who had undergone long-term interferon \u03b2-1b therapy","volume":"53","author":"Ikeda","year":"2013","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.msard.2016.06.012_bib6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2215\/CJN.07311009","article-title":"Treatment with IFN-\u03b1, -\u03b2, or -\u03b3 is associated with collapsing focal segmental glomerulosclerosis","volume":"5","author":"Markowitz","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.msard.2016.06.012_bib7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.msard.2012.02.002","article-title":"Focal segmental glomerulosclerosis secondary to subcutaneous interferon b-1a treatment in a patient with multiple sclerosis","volume":"1","author":"Tornes","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2016.06.012_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-203077","article-title":"Tip variant focal segmental glomerulosclerosis associated with interferon-\u03b2 treatment of multiple sclerosis","author":"Evans","year":"2014","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.msard.2016.06.012_bib9","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1053\/j.ajkd.2012.11.049","article-title":"Nephrotic syndrome in a multiple sclerosis patient receiving long-tern interferon beta therapy","volume":"61","author":"Wallbach","year":"2013","journal-title":"Am. J. Kidney Dis."},{"issue":"2","key":"10.1016\/j.msard.2016.06.012_bib10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/ckj\/sfu016","article-title":"Nephrotic-range proteinuria on interferon-\u03b2 treatment: immune-induced glomerulonephritis or other pathway?","volume":"7","author":"Yuste","year":"2014","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.msard.2016.06.012_bib11","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2147\/DDDT.S42138","article-title":"Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis","volume":"7","author":"Mahe","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.msard.2016.06.012_bib12","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/S0002-9343(99)00113-8","article-title":"Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications","volume":"106","author":"Whelton","year":"1999","journal-title":"Am. J. Med."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034816300967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034816300967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:39:22Z","timestamp":1761899962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034816300967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":12,"alternative-id":["S2211034816300967"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2016.06.012","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon \u03b2 associated nephropathy in a Multiple Sclerosis patient: A case and review","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2016.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}